Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Apple Restores Telegram to App Store After Content Policy Violation 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
PLANO, Texas, April 11, 2016 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Financial Officer, are scheduled to present at the 15th Annual Needham Healthcare Conference in New York, NY.
| Event: | 15th Annual Needham Healthcare Conference |
| Date: | Wednesday, April 13, 2016 |
| Time: | 9:20 am ET |
A webcast of the Company’s presentation will be available by visiting the investor relations section of Nuvectra’s website at www.nuvectramed.com. A webcast replay of the presentation will be available for 90 days.
About Nuvectra Corporation
Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, Chief Financial Officer (972) 668-4106 [email protected] Jennifer Armstrong, Media Relations (214) 618-4823 [email protected] Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 [email protected] Zack Kubow (646) 536-7020 [email protected]
